SANTA CLARA, Calif.–(BUSINESS WIRE)–Agilent Technologies Inc. (NYSE: A) today announced the expansion of Visiopharm’s validated image analysis algorithm to incorporate HercepTest(TM) mAb pharmDx for Dako Omnis, both CE-IVD marked and recently released for sale in Europe. This development enables pathologists to use the Visiopharm HER2 APP for objective decision support in the assessment of HercepTest(TM) mAb pharmDx stained slides, saving valuable time for both pathologists and patients. The Hercep